These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 18191396

  • 1. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC, Awada A, Cameron DA, Cufer T, Martin M, Aapro M.
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [Abstract] [Full Text] [Related]

  • 2. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
    Krol J, Paepke S, Jacobs VR, Paepke D, Euler U, Kiechle M, Harbeck N.
    Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
    [Abstract] [Full Text] [Related]

  • 3. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, ANC Study Group.
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [Abstract] [Full Text] [Related]

  • 4. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW, Treish IM, Zaru L.
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [Abstract] [Full Text] [Related]

  • 5. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N, Friese C.
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [Abstract] [Full Text] [Related]

  • 6. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC.
    J Clin Oncol; 2008 Jan 10; 26(2):290-6. PubMed ID: 18182670
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS.
    Eur J Cancer; 2009 Mar 10; 45(4):608-17. PubMed ID: 19110415
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M, Ganser A, Bokemeyer C, American Society of Clinical Oncology, National Comprehensive Cancer Network, European Organization for Research and Treatment of Cancer.
    Semin Hematol; 2007 Jul 10; 44(3):148-56. PubMed ID: 17631179
    [Abstract] [Full Text] [Related]

  • 12. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH.
    Cancer; 2007 Oct 01; 110(7):1611-20. PubMed ID: 17705197
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH, Shayne M.
    Curr Opin Oncol; 2007 Jul 01; 19(4):299-307. PubMed ID: 17545791
    [Abstract] [Full Text] [Related]

  • 15. Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.
    Lüftner D, Possinger K.
    Onkologie; 2005 Nov 01; 28(11):595-602. PubMed ID: 16249646
    [Abstract] [Full Text] [Related]

  • 16. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.
    J Clin Oncol; 2013 Dec 01; 31(34):4290-6. PubMed ID: 23630211
    [Abstract] [Full Text] [Related]

  • 17. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M.
    Oncology (Williston Park); 2006 Apr 01; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [Abstract] [Full Text] [Related]

  • 18. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
    Pérez Velasco R.
    J Oncol Pharm Pract; 2011 Sep 01; 17(3):225-32. PubMed ID: 20562168
    [Abstract] [Full Text] [Related]

  • 19. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T.
    Gan To Kagaku Ryoho; 2003 Jun 01; 30(6):755-9. PubMed ID: 12852340
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.